Changi General Hospital is a 1000-bed hospital located in Simei, eastern Singapore. It is Singapore's first purpose-built general hospital to serve communities in the east and north-east regions.

During the past decade, Changi General Hospital conducted 98 clinical trials. In the 10-year time frame, 98 clinical trials started and 26 clinical trials were completed, i.e. on average, 26.5% percent of trials that started reached the finish line to date. In the past 5 years, 35 clinical trials started and 17 clinical trials were completed. i.e. 48.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Changi General Hospital" #1 sponsor was "Changi General Hospital" with 60 trials, followed by "Gilead Sciences" with 6 trials sponsored, "Allergan" with 5 trials sponsored, "National University Hospital, Singapore" with 5 trials sponsored and "Medtronic Cardiac Rhythm and Heart Failure" with 5 trials sponsored. Other sponsors include 55 different institutions and companies that sponsored additional 47 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Changi General Hospital" #1 collaborator was "Changi General Hospital" with 16 trials as a collaborator, "Singapore General Hospital" with 11 trials as a collaborator, "National University Hospital, Singapore" with 8 trials as a collaborator, "Tan Tock Seng Hospital" with 8 trials as a collaborator and "Duke-NUS Graduate Medical School" with 7 trials as a collaborator. Other collaborators include 96 different institutions and companies that were collaborators in the rest 78 trials.

According to Clinical.Site data, the most researched conditions in "Changi General Hospital" are "Atrial Fibrillation" (4 trials), "Chronic Hepatitis B" (4 trials), "Diabetes Mellitus" (4 trials), "Gastric Cancer" (4 trials) and "Gastroparesis" (4 trials). Many other conditions were trialed in "Changi General Hospital" in a lesser frequency.

Most popular intervention types in "Changi General Hospital" are "Drug" (51 trials), "Device" (29 trials), "Other" (17 trials), "Procedure" (17 trials) and "Behavioral" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Relamorelin" (3 trials), "Filgotinib" (2 trials), "Placebo to match SEL 18 mg" (2 trials) and "Placebo to match SEL 6 mg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Changi General Hospital" are 133 trials for "All" genders, 4 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are 28 active trials in "Changi General Hospital". 2 are not yet recruiting, 14 are recruiting, 11 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 78 completed trials in Changi General Hospital, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Changi General Hospital, 5 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 47 trials that are defined as “Not Applicable".

Changi General Hospital has several departments that took part in Clinical trials: "Changi General Hospital - Clinical Trials and Research Unit (CTRU)" - 3 trials